Skin symptoms may forewarn mental health risks
en-GBde-DEes-ESfr-FR

Skin symptoms may forewarn mental health risks


Type of research: Not peer reviewed/experimental study/people

Scientists have discovered that mental health patients who have skin conditions may be more at risk of worse outcomes, including suicidality and depression. This work, which may aid in identifying at-risk patients and personalising psychiatric treatment, is presented at the ECNP meeting in Amsterdam.

The researchers looked at 481 patients with a first episode of psychosis (which is the first time an individual experiences a psychotic episode, such as loss of contact with reality, hallucinations and delusions). On testing, 14.5% were found to have dermatological symptoms (24% female, 9.8% male) such as rash, itching, photosensitivity, etc. All patients were given 4 weeks treatment with an antipsychotic and then checked for a range of mental health parameters.

Lead researcher, Dr Joaquín Galvañ (Instituto de Investigación Sanitaria Gregorio Marañón, Madrid) said:

After 4 weeks of follow-up, patients with a first episode of psychosis presenting with skin conditions experienced higher levels of depression and risk of suicide. We found that just 7% of the patients without the initial skin conditions had suicidal thoughts or attempts, in contrast, around 25% of the patients with initial skin conditions had suicidal thoughts or attempts. Initial skin conditions are also linked to greater depression and poorer well-being at follow-up.

This discovery suggests that the presence of skin conditions indicates that these patients are more at risk for worse outcomes than patients who do not have skin conditions after a first episode of psychosis”.

The researchers note that, if confirmed, this finding has the potential to act as an advance marker for mental health risk, similar to the way, a blood test might indicate a greater risk of cancer or heart disease.

The brain and the skin both derive from the same embryonic origin – the ectoderm – prompting the researchers to investigate the relation between the skin and mental health.

Dr Galvañ continued:

“It was already known that between 30% and 60% of people with skin conditions show psychiatric symptoms. What we have done is look at things from the opposite direction; do people with mental health problems have skin conditions, and if so, can this tell us anything useful?

Our findings suggest that dermatological symptoms may represent a marker of illness severity and poor short-term outcomes in the early stages of psychosis, potentially identifying a subgroup of patients with a poorer clinical prognosis who may benefit from early tailored interventions. The reason for the connection is still unclear, but our working hypothesis is that this may be due to the skin and neurological systems having common developmental origins and inflammatory pathways; but this needs to be confirmed. As far as we know this is the first study to show this link in patients with psychosis, so we need follow-up studies to confirm the finding. We also need to understand if this link applies also to a range of other psychiatric conditions, such as bipolar disorder, ADHD, anxiety or depression”.

Commenting, Professor Eric Ruhe (Professor of Difficult-to-Treat Depression at Radboud University, the Netherlands) said:

“This is an interesting association between skin problems and a first episode of psychosis. These results need replication in different cohorts but might indeed show a new link between skin and psychopathology.

As the skin and the brain derive from the same embryonic origin, this would worth pursuing further, both diagnostically and mechanistically (which may be more interesting). For example, this association might be used to culture skin cells to begin to understand which treatment is appropriate”.

This is an independent comment, Professor Ruhe was not involved in this work.


ENDS
This work is presented at the 38th ECNP Congress, taking place in Amsterdam and online 11-14th October 2025, see https://www.ecnp.eu/congress2025/. With more than 7000 participants the ECNP Congress is Europe’s leading platform for the science and treatment of brain disorders.
Regions: Europe, Netherlands, Spain
Keywords: Health, Medical, Well being

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by AlphaGalileo Terms Of Use Privacy Statement